Psychiatry Research: Neuroimaging
Volume 171, Issue 2 , Pages 120-128 , 28 February 2009

Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder

  • Swen Hesse

      Affiliations

    • Department of Nuclear Medicine, University of Leipzig, Stephanstraße 11, 04103 Leipzig, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 341 97 18081; fax: +49 341 97 18069.
    • ,
  • Olaf Ballaschke

      Affiliations

    • Day Clinic for Cognitive Neurology, University Leipzig and Max Planck Institute for Human Cognitive and Brain Science, Leipzig, Germany
    • ,
  • Henryk Barthel

      Affiliations

    • Department of Nuclear Medicine, University of Leipzig, Stephanstraße 11, 04103 Leipzig, Germany
    • ,
  • Osama Sabri

      Affiliations

    • Department of Nuclear Medicine, University of Leipzig, Stephanstraße 11, 04103 Leipzig, Germany

Received 13 April 2007 ,Revised 3 December 2007 ,Accepted 7 January 2008.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual on Mental Disorders. 4th edition. Washington, D.C.: APA; 1994;
  2. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Striatal dopamine transporter availability with [123I]β-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology (Berl). 2005;183:181–199
  3. Booij J, de Jong J, de Bruin K, Knol R, de Win M, van Eck-Smit BLF. Quantification of striatal dopamine transporters with [123I]FP-CIT SPECT is influenced by the SSRI paroxetine: a double-blind, placebo-controlled, crossover study in healthy controls. Journal of Nuclear Medicine. 2007;48:359–366
  4. Buchert R, Schulze O, Wilke F, Berding G, Thomasius R, Petersen K, et al. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults?. Journal of Nuclear Medicine. 2006;47:38–42
  5. Castellanos FX, Elia J, Kruesi MJ, Marsh WL, Gulotta CS, Potter WZ, et al. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology. 1996;14:125–137
  6. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD. Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. European Journal of Nuclear Medicine Molecular Imaging. 2003;30:306–311
  7. Döpfner M, Lehmkugel G. DISYPS-KJ: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV. Bern: Verlag Hans Huber; 2000;
  8. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132–2133
  9. Doyle AE, Willcutt EG, Seidman LJ, Biederman J, Chouinard VA, Silva J, et al. Attention-deficit/hyperactivity disorder endophenotypes. Biological Psychiatry. 2005;57:1324–1335
  10. Dresel S, Krause J, Krause KH, La Fougère C, Brinkbaumer K, Kung HF, et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. European Journal of Nuclear Medicine. 2000;27:1518–1524
  11. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. Journal of Neuroscience. 1998;18:5901–5907
  12. Findling RL, Greenhill LL, McNamara NK, Demeter CA, Kotler LA, O'Riordan MA, et al. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child & Adolescent Psychopharmacology. 2007;17:433–446
  13. Forssberg H, Fernell E, Waters S, Waters N, Tedroff J. Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder. Behavior and Brain Function. 2006;2:40
  14. Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. Annual Review of Pharmacology and Toxicology. 2003;43:261–284
  15. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397–401
  16. Gould GG, Altamirano AV, Javors MA, Frazer A. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biological Psychiatry. 2005;59:408–414
  17. Groß J, Blocher D, Trott GE, Rößler M. Erfassung des hyperkinetischen Syndroms bei Erwachsenen. Nervenarzt. 1999;70:20–25
  18. Gu XH, Zong R, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. Bioorganic Medicine Chemical Letters. 2001;11:3049–3053
  19. Hautzinger M, Bailer M, Worall H, Keller F. Beck-Depression Inventar (BDI). Verlag Hans Huber: Bern; 1995;
  20. Heiser P, Friedel S, Dempfle A, Konrad K, Smidt J, Grabarkiewicz J, et al. Molecular genetic aspects of attention-deficit/hyperactivity disorder. Neuroscience & Biobehavior Review. 2004;28:625–641
  21. Hesse S, Barthel H, Hermann W, Murai T, Kluge R, Wagner A, et al. Regional serotonin transporter availability and depression are correlated in Wilson's disease. Journal of Neural Transmission. 2003;110:923–933
  22. Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, et al. Serotonin and dopamine transporter imaging in patients with obsessive–compulsive disorder. Psychiatry Research: Neuromaging. 2005;140:63–72
  23. Hesse S, Oehlwein C, Barthel H, Schwarz J, Polster D, Wagner A, et al. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. Journal of Neural Transmission. 2006;113:1177–1190
  24. Ito Y, Fujita M, Shimada S, Watanabe Y, Okada T, Kusuoka H, et al. Comparison between the decrease of dopamine transporter and that of l-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse. 1999;31:178–185
  25. Jayanthi LD, Ramamoorthy S. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J. 2005;7:E728–E738
  26. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biological Psychiatry. 2005;57:229–238
  27. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self- Report Scale (ASRS): a short screening scale for use in the general population. Psychological Medicine. 2005;35:245–256
  28. Krakowski M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. Journal of Neuropsychiatry and Clinical Neuroscience. 2003;15:294–305
  29. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neuroscience Letters. 2000;285:107–110
  30. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K, Ackenheil M. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. International Journal of Neuropsychopharmacology. 2002;5:111–113
  31. Krause KH, Dresel SH, Krause J, la Fougère C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neuroscience and Biobehavioral Review. 2003;27:605–613
  32. Krause J, Dresel SH, Krause KH, la Fougère C, Zill P, Ackenheil M. Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele. World Journal of Biological Psychiatry. 2006;7:152–157
  33. Krause J, la Fougère C, Krause KH, Ackenheil M, Dresel SH. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. European Archives of Psychiatry and Clinical Neuroscience. 2005;255:428–431
  34. Kuntsi J, Neale BM, Chen W, Faraone SV, Asherson P. The IMAGE project: methodological issues for the molecular genetic analysis of ADHD. Behavior Brain Function. 2006;2:27
  35. La Fougère C, Krause J, Krause KH, Gildehaus FJ, Hacker M, Koch W, et al. Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nuclear Medicine Communications. 2006;27:733–737
  36. Larisch R, Sitte W, Antke C, Nikolaus S, Franz M, Tress W, et al. Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder. Nuclear Medicine Communications. 2006;27:267–270
  37. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea Ponce Y, Zoghbi SS, et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]β-CIT binding to dopamine transporters in healthy human subjects. Journal of Cerebral Blood Flow and Metabolism. 1994;14:982–994
  38. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biological Psychiatry. 2005;57:1397–1409
  39. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. American Journal of Psychiatry. 2004;161:1948–1956
  40. Meyer JH, Kruger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12:4121–4125
  41. Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. Journal of Nuclear Medicine. 2003;44:839–845
  42. In:  Mombour W,  Zaudig M,  Berger P,  Gutierrez K,  Berner W,  Berger K,  v Cranach M,  Giglhuber O,  v Bose M editor. International Personality Disorder Examination (IPDE), ICD-10 Modul. Bern: Verlag Hans Huber; 1996;
  43. Parsey RV, Hastings RS, Oquendo MA, Simpson N, Arcement J, Huang Y, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. American Journal of Psychiatry. 2006;163:52–58
  44. Rosa-Neto P, Lou HC, Cumming P, Pryds O, Karrebaek H, Lunding J, et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage. 2005;25:868–876
  45. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse. 2006;59:243–251
  46. Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biological Psychiatry. 2005;57:1293–1300
  47. Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl JP, et al. Sex differences in [123I]β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001;41:275–284
  48. van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, et al. Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder. American Journal of Psychiatry. 2002;159:309–312
  49. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. American Journal of Geriatric Psychiatry. 2002;10:36–43
  50. Viggiano D, Vallone D, Ruocco LA, Sadile AG. Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neuroscience and Biobehavioral Review. 2003;27:683–689
  51. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. European Neuropsychopharmacology. 2002;12:557–566
  52. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biological Psychiatry. 2005;57:1410–1415
  53. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, et al. Brain dopamine transporter levels in treatment and drug naive adults with ADHD. Neuroimage. 2007;34:1182–1190
  54. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. American Journal of Psychiatry. 1993;150:885–890

PII: S0925-4927(08)00020-6

doi: 10.1016/j.pscychresns.2008.01.002

Psychiatry Research: Neuroimaging
Volume 171, Issue 2 , Pages 120-128 , 28 February 2009

Article Tools

* Image Usage & Resolution